investorscraft@gmail.com

Intrinsic Value of Bellicum Pharmaceuticals, Inc. (BLCM)

Previous Close$0.00
Intrinsic Value
Upside potential
Previous Close
$0.00
* Our model cannot be used “out of the box” for the valuation of this stock. You can still do your own valuation by changing the valuation input parameters.

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2022-12-31 and quarterly data as of 2023-09-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %-75.8NaN
Revenue, $2NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m28NaN
Operating income, $m-27NaN
EBITDA, $m-27NaN
Interest expense (income), $mNaN
Earnings before tax, $m-25NaN
Tax expense, $m-0NaN
Net income, $m-25NaN

BALANCE SHEET

Cash and short-term investments, $m22NaN
Total assets, $m24NaN
Adjusted assets (=assets-cash), $m2NaN
Average production assets, $m34NaN
Working capital, $m20NaN
Total debt, $m0NaN
Total liabilities, $m4NaN
Total equity, $m20NaN
Debt-to-equity ratio0.000NaN
Adjusted equity ratio-0.899NaN

CASH FLOW

Net income, $m-25NaN
Depreciation, amort., depletion, $m0NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-26NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-26NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m20
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount